Priority review for perioperative durvalumab plus enfortumab vedotin in cisplatin-ineligible MIBC
FDA priority review · Urology Times · 2026-09-25. Number 1 in the UrologyWatch Top 5 for September 26, 2026.
Based on phase 3 VOLGA, where the regimen improved event-free and overall survival versus cystectomy with or without adjuvant therapy. FDA decision expected Q4 2026.
Why it matters: Would give cisplatin-ineligible patients a second perioperative immunotherapy-ADC option alongside EV-pembrolizumab.
Source: Urology Times
Loading today's edition…